| Trial ID: | L1002 |
| Source ID: | NCT00490737
|
| Associated Drug: |
Daptomycin
|
| Title: |
Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End-Stage Renal Disease
|
| Interventions: |
DRUG: daptomycin
|
| Outcome Measures: |
Primary: Pharmacokinetics, Study Day 1, 3, 5 and 7 or 8 | Secondary: Safety and Tolerability, Study Days 1 through 16 or 17
|
| Sponsor/Collaborators: |
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2007-08-12
|
| Completion Date: |
2008-05-12
|
| Results First Posted: |
|
| Last Update Posted: |
2018-01-09
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00490737
|
